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ABSTRACT
Objective Although low infliximab trough
concentrations and antibodies to infliximab (ATI) are
associated with poor outcomes in patients with Crohn’s
disease (CD), the clinical relevance of ATI in patients
with adequate infliximab concentrations is uncertain. We
evaluated this question using an assay sensitive for
identification of ATI in the presence of infliximab.
Design In an observational study, 1487 trough serum
samples from 483 patients with CD who participated in
four clinical studies of maintenance infliximab therapy
were analysed using a fluid phase mobility shift assay.
Infliximab and ATI concentrations most discriminant for
remission, defined as a C-reactive protein concentration
of ≤5 mg/L, were determined by receiver operating
characteristic curves. A multivariable regression model
evaluated these factors as independent predictors of
remission.
Results Based upon analysis of 1487 samples, 77.1%
of patients had detectable and 22.9% had undetectable
infliximab concentrations, of which 9.5% and 71.8%,
respectively, were positive for ATI. An infliximab
concentration of >2.79 μg/mL (area under the curve
(AUC)=0.681; 95% CI 0.632 to 0.731) and ATI
concentration of <3.15 U/mL (AUC=0.632; 95% CI
0.589 to 0.676) were associated with remission.
Multivariable analysis showed that concentrations of
both infliximab trough (OR 1.8; 95% CI 1.3 to 2.5;
p<0.001) and ATI (OR 0.57; 95% CI 0.39 to 0.81;
p=0.002) were independent predictors of remission.
Conclusions The development of ATI increases the
probability of active disease even at low concentrations
and in the presence of a therapeutic concentration of
drug during infliximab maintenance therapy. Evaluation
of strategies to prevent ATI formation, including
therapeutic drug monitoring with selective infliximab
dose intensification, is needed.
INTRODUCTION
Over the past decade, considerable evidence has
accumulated that sensitisation to biological drugs is
an important clinical problem. In 2003, Baert and
colleagues performed a prospective cohort study of
125 patients with Crohn’s disease (CD), which
identified that the presence of an antibody to inflix-
imab (ATI) concentration ≥8 μg/mL was associated
Significance of this study
What is already known on this subject?
▸ C-reactive protein is a marker of disease
activity in patients with Crohn’s disease.
▸ Low or undetectable serum trough
concentrations of infliximab (IFX) are associated
with worse clinical outcomes.
▸ Antibodies to infliximab (ATI) increase the
clearance of drug and are an important
cause of low-serum IFX trough
concentrations.
What are the new findings?
▸ Based on a combined analysis of patient-level
data from four studies that evaluated 483
patients with Crohn’s disease using a fluid
phase mobility shift assay, IFX trough
concentrations >2.79 μg/mL during
maintenance therapy were associated with
remission as measured by C-reactive protein
concentration.
▸ Detectable ATI were associated with greater
disease activity as measured by C-reactive
protein concentration even in the presence of
an adequate IFX trough concentration.
▸ ATI impair the drug’s activity through an
alternative mechanism than only by affecting
its clearance.
How might it impact on clinical practice in
the foreseeable future?
▸ These results support the role of therapeutic
drug monitoring in patients with Crohn’s
disease receiving IFX. We speculate that if the
presence of ATI has a negative effect on the
pharmacodynamics of IFX independent of the
trough concentration, other pharmacokinetics
determinants such as the area under the curve
and maximum serum concentration (Cmax) of
the drug might also be important predictors of
clinical efficacy. Therapeutic drug monitoring
with dose intensification in patients with
undetectable or low IFX trough concentrations
should be evaluated as a strategy to prevent
development of ATI.
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with shorter time to relapse compared with patients with low-
titre ATI.1 Furthermore, patients with ATI had a greater risk of
hypersensitivity reactions. Although subsequent studies have
attempted to define an ATI concentration that correlates with
clinical outcomes,2 3 differences in assay design,4 5 the some-
times transient nature of ATI expression3 6 7 and the inability of
conventional assays to measure ATI in the presence of drug have
made identification of such a relationship problematic.
Nevertheless, a recent meta-analysis that evaluated 1378 patients
with IBD who received treatment with infliximab (IFX) showed
that the pooled risk ratio for loss of clinical response in patients
with ATI was 3.2 (95% CI 2.0 to 4.9; p<0.0001) in comparison
with control patients without ATI.8 Considerable evidence exists
that higher IFX concentrations are associated with greater clin-
ical efficacy in patients with IBD.2 9–15 For example, in
ACCENT I,16 a multicentre trial that evaluated IFX induction
therapy in patients with active CD, patients who failed to
respond to therapy had lower serum IFX concentrations than
those with a sustained response (1.9 and 4.0 μg/mL, respect-
ively; p=0.03).17 Collectively, these data indicate that both pres-
ence of ATI and low IFX concentrations are associated with
worse clinical outcomes. As a consequence, the use of thera-
peutic drug monitoring (TDM) has been advocated to improve
clinical decision making in patients with a secondary loss of
response to IFX.18 19 These observations also hold out the pos-
sibility that dose optimisation based on TDM during induction,
prior to recurrence of symptoms, and possibly prior to ATI for-
mation might result in better outcomes.20 21 However, analysis
of the impact of ATI on IFX pharmacokinetics has been hin-
dered by the inability of most assays to detect ATI in the pres-
ence of IFX. Thus, it has not been possible to determine
whether the negative effects of ATI on clinical efficacy are solely
the consequence of low-trough drug concentrations (i.e.
whether patients with ATI and low drug concentrations are
entirely a subset of patients with low-drug concentrations) or
whether ATI might also impair other measures of drug expos-
ure, such as the maximum serum concentration (Cmax) or the
area under the concentration time curve (AUC), which are crit-
ical to the pharmacodynamics of IFX (even when drug is
present). Therefore, an enhanced understanding of the relevance
of ATI in patients with a detectable serum concentration of IFX
is potentially important.
Based on these considerations, we used a homogenous mobil-
ity shift drug-tolerant assay able to measure ATI in the presence
of IFX to evaluate the relationship between serum IFX trough
concentration, ATI concentration and disease activity in a large
population of patients with CD.
MATERIALS AND METHODS
Study objectives
Our study had two objectives. First, we wished to determine the
IFX trough concentration during maintenance therapy that best
correlated with C-reactive protein (CRP)-defined remission as a
surrogate for clinical remission. A CRP concentration of ≤5 mg/L
was defined as remission. CRP was chosen to define disease activity,
in distinction to clinical symptoms, because numerous studies have
demonstrated that a poor correlation exists between symptoms and
inflammation defined by colonoscopy, serum acute-phase reactants
such as CRP or faecal biomarkers such as calprotectin.22 23
A second goal was to evaluate the relationship between CRP con-
centration as a measure of disease activity, the IFX trough concen-
tration and the presence of ATI in four distinct groups of patients:
(1) IFX trough concentration ≥3 μg/mL and ATI negative; (2) IFX
trough concentration <3 μg/mL and ATI negative; (3) IFX trough
concentration ≥3 μg/mL and ATI positive and (4) IFX trough con-
centration <3 μg/mL and ATI positive. The rationale for these sub-
group analyses is based on the hypothesis that the indirect
correlation between IFX and disease activity differs by ATI status.
Specifically, we wished to determine whether ATI was a predictor
of disease activity independent of IFX trough concentration.
Study design and conduct
Assays were performed on 1487 trough serum samples from
483 patients with CD treated with maintenance IFX therapy
who had previously participated in one of four prospective ran-
domised controlled trials or cohort studies: the COMMIT
trial,24 the Leuven transient ATI study,3 the Canadian
Multicentre study25 and the Leuven antimetabolite withdrawal
study.26
Study population and evaluations
Trough serum samples were obtained during each study. From
both of the Leuven studies, the only samples included were
those available at time that the current study was designed and
implemented. The COMMIT study24 was a randomised con-
trolled trial that evaluated the efficacy of combination therapy
with methotrexate and IFX. The Leuven transient ATI study3
examined the effect of transient ATI formation on IFX pharma-
cokinetics and clinical response. The Canadian Multicentre
study25 was a prospective analysis of the relationship between
IFX concentrations, ATI concentrations and clinical disease
activity in patients receiving maintenance therapy. The fourth
study26 evaluated the efficacy of continued antimetabolite
therapy in patients, after receiving combination therapy with
IFX during the first six months of therapy. These parent studies
enrolled adult patients with moderate-to-severe CD.
Demographic data collected included the age at diagnosis, the
age at first IFX infusion and the use of concomitant treatment
with azathioprine or methotrexate, as well as the serum sample
collection date. Each of these studies collected trough serum
samples for analysis of serum IFX, ATI and CRP concentration.
Serum CRP was measured with the Vascular Injury Panel 2
(human) V-PLEX Kit (Meso Scale Discovery, Rockville,
Maryland, USA) on the MSD platform (Meso Scale Discovery,
Rockville, Maryland, USA) with a lower limit of quantitation
(LLOQ) of 0.7 μg/L. Serum IFX and ATI were measured using a
previously described commercially available homogenous mobil-
ity shift assay (Prometheus Laboratories, San Diego, California,
USA).27 The LLOQ for the presence of IFX and ATI in this
assay was 0.98 μg/mL and 3.13 U/mL, respectively. By using a
preanalytical acid dissociation step, this drug-tolerant assay can
detect ATI in the presence of up to 60 μg/mL IFX.27 To reduce
variability, all of the samples were reanalysed in batch.
Statistical analyses
Receiver operating characteristic (ROC) curves were used to
determine the IFX and ATI concentration thresholds that best
discriminated remission, defined as a CRP concentration of
≤5 mg/L. The AUC of the ROC curve along with the 95% CI
were adjusted for repeated observations per subject.28 A multi-
variable logistic model assessed multiple clinical and laboratory
factors as independent predictors of a CRP concentration of
>5 mg/L. Factors included in the modelling process were study,
gender, age at diagnosis, age at collection, days since first IFX
infusion, age at first IFX, methotrexate use, azathioprine use,
IFX concentration <3 μg/mL, ATI concentration ≥3.13 U/mL
and an IFX–ATI interaction term. Factors not significant at the
0.05 level were removed by backwards elimination. A
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multivariable logistic model evaluated IFX concentration <3 μg/
mL, ATI concentration ≥3.13 U/mL and interval (days
in-between samples) in a ‘current sample’ as independent pre-
dictors of a CRP concentration of >5 mg/L in a ‘future sample’.
Only samples with an interval of 56±14 days in-between
‘current’ and ‘future’ sample were taken into account for each
patient. Two-way and three-way interactions between all the
variables IFX, ATI and interval between samples were included
in the model to investigate whether the effects of IFX and ATI
were dependent on each other and dependent on time. The
model was adjusted for study, days between first IFX and first
sample and baseline CRP in the ‘current’ sample. All models
were adjusted for multiple observations per subject, as a random
effect.
Ethical considerations
All serum samples analysed were obtained during the execution
of four separate parent clinical trials. The informed consent
process complied with the International Conference on
Harmonisation–Good clinical practice and all applicable regula-
tory requirement(s). The consent of subjects included the use of
the collected data and serum for other medical purposes.
Therefore, additional consent for the current study was not
obtained. Each study was reviewed by a research ethics board at
the respective site where the initial study was conducted
(Western University for the COMMIT Trial and the Canadian
Multicentre Trial, and the University of Leuven for the transient
ATI study and the antimetabolite withdrawal study). All subject
information used in this study was de-identified with respect to
the subject identification number and investigational site. The
serum samples were assayed following conclusion of the four
original parent studies and did not affect patients’ treatment
and/or well-being.
RESULTS
Study population
Samples from 483 patients were analysed, of whom 236
(48.9%) were men. The mean age of the patients at diagnosis
was 28.5±12.9 years. Eighty-five patients (17.6%) received con-
comitant treatment with methotrexate while 140 patients (29%)
received concomitant azathioprine. A total of 1487 serum
samples were analysed with a median of 2 (range 1–26) samples
per patient. Demographic information and sample character-
istics are summarised in table 1.
Overall the median (IQR) CRP concentration of the sample
cohort was 3.6 (IQR 1.0–12.7) mg/L. Of the 1487 serum
samples, 6.5% (n=96) were IFX and ATI negative, 69.8%
(n=1038) were IFX positive and ATI negative, 16.4% (n=244)
were IFX negative and ATI positive and 7.3% (n=109) were
both IFX and ATI positive (figure 1). Samples that were positive
for ATI had a significantly lower likelihood of having detectable
IFX compared with ATI-negative samples (OR 0.041; 95% CI
0.030 to 0.056; p<0.001).
Outcomes
Based on ROC curve analysis, an IFX concentration cut-off of
>2.79 μg/mL (AUC=0.681; 95% CI 0.632 to 0.731) was asso-
ciated with remission (77.6% specificity, 52.5% sensitivity), as
seen in figure 2. When the IFX trough concentration was divided
into quartiles, a significant concentration-dependent effect was
observed on CRP concentration (p<0.001) (figure 3A) and a
linear trend was observed (p<0.001).
Based on ROC curve analysis, an ATI concentration cut-off of
<3.15 U/mL (AUC=0.632; 95% CI 0.589 to 0.676) was
associated with remission (87.4% specificity, 38.0% sensitivity).
Only taking ATI-positive samples into account (n=342), after
stratification per quartile, a concentration-dependent trend was
observed on CRP concentration (p=0.07) (figure 3B).
Moreover, a significant linear relationship was found, explaining
that at least a part of the association with CRP can be explained
by a trend across the four ATI quartiles (p=0.025). Combining
both factors IFX and ATI as predictors of disease activity
increased the AUC of the ROC curve to 0.701.
Overall, 117 out of 483 patients (24.2%) had detectable ATI
on at least one time point during follow-up. The median CRP
concentration was lower in ATI-negative samples compared with
ATI-positive samples (respectively 2.4 vs. 11.9 mg/L; p<0.001).
In ATI-negative samples stratified according to IFX concentra-
tion, the median CRP concentration was significantly lower
when the serum IFX concentration was ≥3 μg/mL compared
with <3 μg/mL (respectively 2.0 vs. 6.0 mg/L; p<0.001).
However, in ATI-positive samples, the median CRP concentra-
tion was similar in these two groups (respectively 11.9 vs.
11.6 mg/L), although significantly different after correcting for
multiple observations per patient (p=0.019) (figure 4). In an
exploratory analysis, omitting the samples from the Leuven tran-
sient ATI study, we found that CRP concentrations were numer-
ically lower but the same effect was observed, in that CRP
concentrations were elevated in ATI-positive samples despite an
IFX concentration of ≥3 μg/mL (7.9 mg/L) or <3 μg/mL
(9.2 mg/L) (p=0.004).
Univariate analyses demonstrated significant associations
between originating study, presence of ATI and IFX concentra-
tion and the presence of active disease (CRP concentration
>5 mg/L). However, multivariable analysis retained IFX <3 μg/
mL (OR 1.8; 95% CI 1.3 to 2.5; p<0.001) and detectable ATI
(≥3.15 U/mL) (OR 1.8; 95% CI 1.2 to 2.6; p=0.002) as the
only independent predictors of this outcome. The interaction
between IFX and ATI concentrations was also evaluated and
was not significant (p=0.116). For the multivariable logistic
model evaluating IFX, ATI and interval (between samples) in a
‘current’ sample as independent predictors of a CRP concentra-
tion of >5 mg/L in a ‘future’ sample, there were 454 patients
with a complete set of IFX, ATI and CRP on at least two con-
secutive time points with no more than 56±14 days in-between
samples. After correcting for study, days between first IFX and
first sample and baseline CRP, we observed that both IFX
<3 μg/mL (p=0.035) and ATI ≥3.13 U/mL (p=0.006) in a
‘current’ sample were able to predict a CRP concentration of
>5 mg/L in a ‘future’ sample. The interval between ‘current’
and ‘future’ sample was not found to be a predictor of CRP
(p=0.466). IFX and ATI were found to independently predict
CRP and independent of the time in-between samples as none
of the two-way or three-way interactions between the variables
IFX, ATI and interval between samples were significant.
DISCUSSION
This study, which evaluated 1487 trough serum samples from
483 patients with CD who received maintenance IFX therapy in
four parent studies, to our knowledge is the largest evaluation
of the relationship between IFX trough concentrations, ATI and
clinical efficacy that has been reported. Importantly, the use of a
drug-tolerant assay allowed us to assess the relevance of detec-
tion of ATI in the presence of an adequate IFX trough
concentration.
These results confirm the existence of a strong inverse correl-
ation between IFX trough concentration and CRP-defined
remission. Notably, a linear test for trend was highly significant
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for these factors supporting the presence of an ‘exposure-effect
relationship’. In ROC curve analysis, an IFX trough concentra-
tion of ≤2.79 μg/mL best discriminated disease activity (OR
2.13; 95% CI 1.54 to 2.96), suggesting that this value can be
used as a benchmark in clinical practice; however, confirmatory
studies are needed. Prospectively acquired data re-confirming
this threshold would provide additional validity.
This study also provides new insights into the relationship
between ATI and disease activity. Use of the drug-tolerant fluid
phase mobility shift assay allowed us to assess the role of ATI in
the presence of IFX. A strong correlation was observed between
the presence of ATI and the likelihood of active disease defined
by a CRP concentration of >5 mg/L. Interestingly, a linear test
for trend for CRP concentration across different ATI quartiles
was significant, suggesting a ‘causal relationship’ between both
these factors. ROC curve analysis revealed an ATI concentration
of ≥3.15 U/mL best discriminated active disease (OR 2.22; 95%
CI 1.56 to 3.15). However, it was notable that in the subset of
samples that were positive for ATI and also had an IFX trough
concentration ≥3 μg/mL, a similar proportion of samples had
CRP >5 mg/L compared with the subset of samples that were
ATI positive and had an IFX trough concentration <3 μg/mL
Table 1 Patient demographics within each study and the combined data set*
COMMIT Canadian multicentre Transient ATI
IMM
withdrawal Combined
Patients
Patients—no. 49 327 25 82 483
Men—no. (%) 28 (57) 157 (48) 11 (44) 40 (49) 236 (49)
Age at diagnosis 29.5±13.3 29.3±13.2 26.8±11.6 25.5±11.3 28.5±12.9
Age at first sample collection 39.0±14.0 39.9±12.9 40.3±12.7 35.7±13.8 39.1±13.2
Age at first infliximab 38.6±14.1 38.5±13.0 39.9±12.5 33.7±13.8 37.7±13.3
Patients ever IFX ≥3 μg/mL—no. (%) 44 (90) 237 (73) 15 (60) 75 (92) 371 (77)
Patients ever ATI positive—no. (%) 9 (18) 73 (22) 23 (92) 12 (15) 117 (24)
Patients ever receiving MTX—no. (%) 23 (47) 30 (9) 9 (36) 23 (28) 85 (18)
Patients ever receiving AZA—no. (%) 0 (0) 81 (25) 0 (0) 59 (72) 140 (29)
Serum samples
Serum samples—no. 169 637 314 367 1487
Samples per subject† 4 (1–4) 2 (1–2) 11 (2–26) 4 (1–13) 2 (1–26)
Time between first infliximab and sample—months† 7 (6.5–9) 17 (11–26) 17 (9–40) 24 (17–50) 17 (9–29)
Serum samples IFX ≥3 μg/mL—no. (%) 135 (80) 417 (66) 102 (33) 295 (80) 949 (64)
Serum samples ATI positive—no. (%) 19 (11) 115 (18) 183 (58) 36 (10) 353 (24)
CRP—mg/L 5.9±11.1 11.2±22.9 24.4±32.5 8.5±13.8 12.6±23.2
CRP†—mg/L 2.1 (0.8–6.2) 3.0 (0.8–10.0) 11.7 (3.1–29.7) 2.4 (0.7–9.7) 3.6 (1.0–12.7)
*Mean±SD.
† Values are median and IQR.
ATI, antibodies to infliximab; AZA, azathioprine; CRP, C-reactive protein; IFX, infliximab; IMM, immunosuppressive; MTX, methotrexate.
Figure 1 XY plot of infliximab (IFX) and antibody to infliximab (ATI)
concentration of all 1487 samples. Lower limit of quantitation (LLOQ)
for IFX and ATI using the homogenous mobility shift assay was
respectively 0.98 μg/mL and 3.13 U/mL. Seventeen data points were
outside the axis limits: 4/17 samples had IFX >35 μg/mL (none were
positive for ATI) and 13/17 samples had ATI >90 U/mL (none were
positive for IFX). Positive (+) and negative (–) signs represent
respectively samples with detectable and undetectable IFX or ATI.
Figure 2 Receiver operating characteristic curve analysis showing the
infliximab threshold that best discriminated disease activity, as
measured by C-reactive protein (concentration ≤5 mg/L was defined as
inactive disease).
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(respectively 36/54 samples (66.7%) vs. 199/288 samples
(69.1%); p=0.084). Consistent with this observation, the pres-
ence of ATI was confirmed as an independent predictor of
active disease in the multivariable model. This observation sug-
gests that ATI negatively influence the efficacy of IFX even in
low concentrations and in the presence of an adequate trough
drug concentration. These results point towards an alternative
mechanism of action of how ATI impair drug activity as it was
previously thought that this was mainly driven by an effect on
the pharmacokinetics of the drug causing a faster clearance. Our
results support the hypothesis that at least in some patients the
effect of ATI is mediated through binding of the ATI to the idio-
type of IFX, thereby blocking the binding to tumour necrosis
factor (TNF) and directly neutralising the drug’s activity. Most
likely, in the majority of patients, it is a combination of both
mechanisms that will ultimately lead to impaired drug activity.
In fact, it is believed that when only one or two endogenous
antidrug antibodies bind to an exogenous protein, this has no
effect on its half-life and may actually increase and approach
that of endogenous IgG. On the other hand, when three or
more endogenous antidrug antibodies bind to the exogenous
protein simultaneously, the resulting immune complex will be
eliminated rapidly through phagocytosis, increasing the clear-
ance and decreasing the half-life of the drug.29 Aside from char-
acterising the neutralising capacity of endogenous antidrug
antibodies and complex formation in vivo, future research
should evaluate the role of other pharmacokinetic parameters
such as the AUC30 and Cmax
31 as these might prove to be
important determinants of the pharmacokinetic/pharmacody-
namic relationship that are negatively affected by ATI.
Our study has several clinical implications. Identification of
optimum IFX trough and ATI threshold concentrations should
facilitate TDM using a drug-tolerant assay. Currently, the most
common application of TDM is for the evaluation of patients
with a secondary loss of response. In this paradigm, patients
with subtherapeutic IFX concentrations who lack ATI may
benefit from dose intensification. A second group consists of
patients who are ATI negative and have an adequate IFX trough
concentration. Although scientific evidence is lacking, inflamma-
tion in these individuals may be driven by processes that are not
TNF dependent. Accordingly, a switch to an ‘out of class’ agent
such as vedolizumab might be optimal.32 In a third group of
patients, those with absent drug and a high concentration of
ATI, a switch to another TNF antagonist is likely optimal since
the patient originally responded to this class of drugs and, for
the most part, ATI does not neutralise other agents. Finally,
little is known regarding the optimal management of patients
with detectable concentrations of both IFX and ATI. Dose escal-
ation may be considered in those patients as well as a switch to
another TNF antagonist as from our data it was observed that
even low ATI in the presence of IFX are an independent pre-
dictor for elevated CRP (>5 mg/L).
Apart from the emerging role in the management of patients
with secondary loss of response, other important applications of
TDM are likely to evolve including prospective dose optimisa-
tion with selective dose intensification or reduction. This strat-
egy could improve therapeutic efficacy, reduce the risk of ATI
formation and decrease the cost of care.18 33 34 Studies such as
the TAXITand TAILORIX trials, in which patients are randomly
assigned to standard care or to prospective dose optimisation
based on TDM, have been initiated. The TAXIT trial showed
that, during maintenance therapy with IFX, better clinical out-
comes were achieved when a threshold IFX trough concentra-
tion of ≥3 μg/mL was targeted and that patients with an IFX
trough concentration of >7 μg/mL could be safely dose
de-escalated, resulting in significantly lower drug costs without
affecting the proportion of patients in remission.35 After this
Figure 3 Median C-reactive protein (CRP) concentration (mg/L) per
quartile of infliximab trough (IFX) concentration (A) and antibody to
infliximab (ATI) concentration (B). IFX concentration (μg/mL) quartiles
(Q) were Q1 <1.27; Q2 ≥1.27 to <4.68; Q3 ≥4.68 to <8.59 and Q4
≥8.59 and ATI concentration quartiles (Q) for ATI-positive samples
were Q1 <6.23; Q2 ≥6.23 to <11.32; Q3 ≥11.32 to <21.06 and Q4
≥21.06.
Figure 4 Whiskers boxplot (5th–95th centile) representing the
C-reactive protein concentration (mg/L) in samples with an infliximab
(IFX) trough concentration above or below the threshold of 3 μg/mL,
both for antibody to IFX (ATI) negative (<3.13 U/mL) and ATI positive
(≥3.13 U/mL) samples.
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initial dose optimisation, no additional benefit was observed to
continue concentration-based dosing over clinically based
dosing throughout the first year.36 The prospectively acquired
data from TAXIT confirm the IFX trough concentration thresh-
old that was found here, and its validity across different assay
formats as in the TAXIT trial a clinically validated ELISA was
used to measure IFX concentrations.5
Our study had several limitations. First, it was retrospectively
designed. However, data were derived from four parent cohorts
that evaluated patients with CD receiving IFX maintenance
therapy and where trough serum samples were prospectively
collected. Second, disease activity was measured by CRP con-
centration, a biomarker for inflammation, rather than by the
gold standard of colonoscopy. During the time the parent
studies were designed, endoscopic evaluation was not routinely
used as an outcome measure in clinical research. Nevertheless,
CRP has previously been shown to be an accurate marker to
predict reactivation of disease activity in patients with CD
treated with IFX therapy.37 Finally, the IFX and ATI thresholds
were not independently confirmed in a separate population of
patient samples. This is an important limitation that will be
redressed in a follow-up study.
In conclusion, we have defined trough IFX and ATI concen-
tration thresholds that are independently associated with remis-
sion in CD. Further investigation into the mechanisms by which
ATI negatively affect the efficacy of IFX and strategies to
prevent the development of sensitisation are a research priority.
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